Table 1.
Baseline clinical data, medications, and complications.
| (A) Clinical data | N = 87 |
| Basic data | |
| Age (years) | 68.1 (0.9) |
| Male/female | 20/67 |
| Duration (months) | 136.0 (9.7) |
| Disease activity indices | |
| DAS28-ESR | 4.69 (0.10) |
| DAS28-CRP | 4.02 (0.10) |
| SJC | 5.0 (0.3) |
| TJC | 5.6 (0.5) |
| pVAS (mm) | 41.9 (2.4) |
| eVAS (mm) | 42.3 (1.8) |
| PainVAS (mm) | 46.0 (2.4) |
| mHAQ | 0.71 (0.07) |
| CDAI | 19.2 (0.9) |
| SDAI | 20.3 (0.9) |
| Disease biomarkers | |
| ESR (mm/hr) | 36.9 (3.0) |
| CRP (mg/dl) | 1.2 (0.2) |
| RF (IU/ml) | 257 (60) |
| ACPA (U/ml) | 16.9 (2.6) |
| Hb (g/dl) | 12.6 (0.1) |
| MMP3 (ng/ml) | 238 (74) |
| TNF (pg/ml) | 2.3 (0.6) |
| IL-6 (pg/ml) | 17.2 (2.7) |
| (B) Medications | N = 173 |
| Methotrexate | 55 |
| Steroid | 44 |
| Bucillamine | 30 |
| Salazosulfapyridine | 17 |
| Tacrolimus | 14 |
| Leflunomide | 5 |
| Injectable gold | 4 |
| Others | 4 |
| None | 1 |
| (C) Complications | N = 140 |
| Osteoporosis | 25 |
| Pulmonary interstitial diseases | 16 |
| Hypertension | 13 |
| Post cancer/benign tumor | 12 |
| Chronic pulmonary disease | 10 |
| Diabetes mellitus | 9 |
| Chronic infectious diseases | 8 |
| Rapid radiographic progression | 7 |
| Lumbar degenerative diseases | 7 |
| Post arthroplasty | 6 |
| Cardiac diseases | 5 |
| Chronic metabolic disease | 5 |
| Cervical degenerative disease | 5 |
| Others | 12 |
DAS28: disease activity score with 28 joint counts; SJC: swollen joint counts; TJC: tender joint counts; pVAS (eVAS): patient's (evaluator's) visual analogue scale; mHAQ: modified health assessment questionnaire; CDAI: clinical disease activity index; SDAI: simplified disease activity index; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; RF: rheumatoid factor; ACPA: anticyclic citrullinated peptide antibody; Hb: hemoglobin; MMP: matrix metalloproteinase-3; TNF: tumor necrosis factor alpha; IL-6: interleukin-6. Data are shown as mean (standard error).